Long-Term ZORYVE Data Published, Reinforcing Efficacy and Safety for Pediatric Atopic Dermatitis
ARQT has more than doubled off its 52-week low of $11.86.
Summary
Arcutis Biotherapeutics announced the publication of positive long-term safety and efficacy data for ZORYVE (roflumilast) Cream 0.05% in children aged 2-5 with mild-to-moderate atopic dermatitis in the journal Pediatric Dermatology. This data, from the Phase 3 open-label extension study, supported the FDA approval of ZORYVE for this indication in October 2025. The publication reinforces ZORYVE's profile, demonstrating maintained and improved efficacy over 56 weeks and a favorable safety profile, which is crucial for a chronic condition in a young patient population. This formal scientific validation adds credibility and can support broader physician adoption, strengthening the commercial outlook for a key product. Investors will continue to monitor the commercial rollout and sales performance of ZORYVE in this expanded pediatric indication.
At the time of this announcement, ARQT was trading at $24.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $11.86 to $31.77. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.